Fig. 2From: Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trialsThe total number of MedDRA preferred terms (Adverse Events) reported in clinical study reports (CSRs) and journal publications across all five trials. Footnote: Total: Total number of individual MedDRA preferred terms related to AEs reported across the CSR and journal publication for a trialBack to article page